Vesna Brglez

1.3k total citations
43 papers, 815 citations indexed

About

Vesna Brglez is a scholar working on Nephrology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Vesna Brglez has authored 43 papers receiving a total of 815 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Nephrology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Infectious Diseases. Recurrent topics in Vesna Brglez's work include Renal Diseases and Glomerulopathies (18 papers), SARS-CoV-2 and COVID-19 Research (9 papers) and COVID-19 Clinical Research Studies (8 papers). Vesna Brglez is often cited by papers focused on Renal Diseases and Glomerulopathies (18 papers), SARS-CoV-2 and COVID-19 Research (9 papers) and COVID-19 Clinical Research Studies (8 papers). Vesna Brglez collaborates with scholars based in France, Slovenia and United States. Vesna Brglez's co-authors include Barbara Seitz‐Polski, Gérard Lambeau, Toni Petan, Vincent Esnault, Sonia Boyer‐Suavet, Sylvia Benzaken, Marion Crémoni, Kévin Zorzi, Christine Payré and Jože Pungerčar and has published in prestigious journals such as Nature Communications, Biochemical and Biophysical Research Communications and Methods in enzymology on CD-ROM/Methods in enzymology.

In The Last Decade

Vesna Brglez

39 papers receiving 810 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vesna Brglez France 18 294 188 167 158 150 43 815
Giuseppe De Palma Italy 17 236 0.8× 339 1.8× 51 0.3× 208 1.3× 95 0.6× 36 886
Daniel Guldager Kring Rasmussen Denmark 15 151 0.5× 148 0.8× 92 0.6× 76 0.5× 82 0.5× 45 777
Margherita Gigante Italy 21 195 0.7× 440 2.3× 93 0.6× 362 2.3× 283 1.9× 38 1.2k
Yalan Bi China 16 72 0.2× 163 0.9× 85 0.5× 48 0.3× 146 1.0× 51 718
Jie Ding China 16 214 0.7× 604 3.2× 79 0.5× 197 1.2× 178 1.2× 57 1.2k
Laurette Geldenhuys Canada 18 109 0.4× 339 1.8× 61 0.4× 38 0.2× 104 0.7× 43 853
Philip Ruiz United States 17 88 0.3× 103 0.5× 51 0.3× 260 1.6× 96 0.6× 30 795
A Rifai United States 18 369 1.3× 255 1.4× 96 0.6× 325 2.1× 56 0.4× 33 889
Gretchen S. Crary United States 16 202 0.7× 242 1.3× 50 0.3× 78 0.5× 214 1.4× 22 955
Irene Agraz Spain 14 222 0.8× 102 0.5× 71 0.4× 96 0.6× 137 0.9× 39 533

Countries citing papers authored by Vesna Brglez

Since Specialization
Citations

This map shows the geographic impact of Vesna Brglez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vesna Brglez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vesna Brglez more than expected).

Fields of papers citing papers by Vesna Brglez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vesna Brglez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vesna Brglez. The network helps show where Vesna Brglez may publish in the future.

Co-authorship network of co-authors of Vesna Brglez

This figure shows the co-authorship network connecting the top 25 collaborators of Vesna Brglez. A scholar is included among the top collaborators of Vesna Brglez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vesna Brglez. Vesna Brglez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Teisseyre, Maxime, Alexandre Destère, Marion Crémoni, et al.. (2025). Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial. BMJ Open. 15(4). e093920–e093920.
2.
Teisseyre, Maxime, Marco Allinovi, Vincent Audard, et al.. (2024). Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies. Kidney International Reports. 10(3). 753–761. 8 indexed citations
3.
Buscot, Matthieu, Marion Crémoni, Vesna Brglez, et al.. (2023). Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses. Frontiers in Immunology. 14. 1145652–1145652. 1 indexed citations
4.
Lazareth, Hélène, Adrien Flahault, Vesna Brglez, et al.. (2023). Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors. Kidney International Reports. 8(9). 1892–1898.
5.
Brglez, Vesna, Kévin Zorzi, Maxime Teisseyre, et al.. (2023). Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France. Journal of Clinical Immunology. 43(8). 1724–1739. 7 indexed citations
6.
Fabre, Roxane, Michel Ticchioni, Christian Pradier, et al.. (2023). Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study. Frontiers in Immunology. 14. 1136723–1136723. 3 indexed citations
7.
Teisseyre, Maxime, Vesna Brglez, Marion Crémoni, et al.. (2023). Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy. Clinical Journal of the American Society of Nephrology. 18(6). 785–787. 10 indexed citations
8.
Occelli, Céline, Jean‐Marie Guigonis, Sabine Lindenthal, et al.. (2022). Untargeted plasma metabolomic fingerprinting highlights several biomarkers for the diagnosis and prognosis of coronavirus disease 19. Frontiers in Medicine. 9. 995069–995069. 10 indexed citations
9.
Crémoni, Marion, Kévin Zorzi, Maxime Teisseyre, et al.. (2022). Low baseline IFN-γ response could predict hospitalization in COVID-19 patients. Frontiers in Immunology. 13. 953502–953502. 20 indexed citations
10.
Levraut, Michaël, Lydiane Mondot, Mikaël Cohen, et al.. (2022). Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities. Frontiers in Immunology. 13. 864133–864133. 9 indexed citations
11.
Brglez, Vesna, Marion Crémoni, Kévin Zorzi, et al.. (2021). Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. Frontiers in Medicine. 7. 603961–603961. 30 indexed citations
12.
Bresch, Saskia, Barbara Seitz‐Polski, Claude Desnuelle, et al.. (2021). Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. Neurotherapeutics. 18(2). 938–948. 14 indexed citations
13.
Teisseyre, Maxime, Marion Crémoni, Sonia Boyer‐Suavet, et al.. (2021). Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy. Frontiers in Immunology. 12. 738788–738788. 26 indexed citations
14.
Crémoni, Marion, Kévin Zorzi, Sonia Boyer‐Suavet, et al.. (2021). Humoral and Cellular Response of Frontline Health Care Workers Infected by SARS-CoV-2 in Nice, France: A Prospective Single-Center Cohort Study. Frontiers in Medicine. 7. 608804–608804. 7 indexed citations
15.
Ghiggeri, Gian Marco, Barbara Seitz‐Polski, Joana Justino, et al.. (2020). Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy. Clinical Journal of the American Society of Nephrology. 15(12). 1762–1776. 21 indexed citations
16.
Boyer‐Suavet, Sonia, Marine Andreani, Vesna Brglez, et al.. (2020). Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab. Frontiers in Immunology. 10. 3069–3069. 74 indexed citations
17.
Brglez, Vesna, Sonia Boyer‐Suavet, Kévin Zorzi, et al.. (2020). Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial. Frontiers in Medicine. 7. 412–412. 6 indexed citations
18.
Kocbek, Vida, Nick A. Bersinger, Vesna Brglez, et al.. (2014). Phospholipase A2 group IIA is elevated in endometriomas but not in peritoneal fluid and serum of ovarian endometriosis patients. Gynecological Endocrinology. 31(3). 214–218. 8 indexed citations
19.
Brglez, Vesna, Gérard Lambeau, & Toni Petan. (2014). Secreted phospholipases A2 in cancer: Diverse mechanisms of action. Biochimie. 107. 114–123. 61 indexed citations
20.
Pucer, Anja, Vesna Brglez, Christine Payré, et al.. (2013). Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival. Molecular Cancer. 12(1). 111–111. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe De Palma Breakdown of academic impact, for papers by Daniel Guldager Kring Rasmussen Breakdown of academic impact, for papers by Margherita Gigante Breakdown of academic impact, for papers by Yalan Bi Breakdown of academic impact, for papers by Jie Ding Breakdown of academic impact, for papers by Laurette Geldenhuys Breakdown of academic impact, for papers by Philip Ruiz Breakdown of academic impact, for papers by A Rifai Breakdown of academic impact, for papers by Gretchen S. Crary Breakdown of academic impact, for papers by Irene Agraz
Rankless by CCL
2026